Defendant
1 case as defendant.
I'll research this company before writing the profile.
Let me verify a few more details on their products and litigation context.
Company overview. Solaris Pharma Corporation ("Solaris") is a privately held specialty pharmaceutical company headquartered in Bridgewater, New Jersey, founded in 2014 by Lakshmi Raghavan. It runs an R&D and manufacturing site in Somerset, NJ. It is not publicly traded and no parent company is disclosed. Third-party aggregators (Tracxn, RocketReach, Kona Equity) report roughly $23 million raised across two rounds and headcount in the low tens to about 40 employees; no official revenue or headcount figure is published, and aggregator revenue estimates are unverified. Reported leadership is inconsistent across sources (both Satish Pejaver and Shalin Jani appear as CEO/President), so the current officer slate should be treated as unconfirmed.
Products / operations. Solaris develops and commercializes complex generic and specialty pharmaceuticals, concentrated in topical/transdermal and sterile ophthalmic dosage forms. FDA approval records (Drugs@FDA, DrugPatentWatch) list ANDAs for tazarotene gel (0.05%/0.1%) and cream, clindamycin phosphate/tretinoin gel, estradiol transdermal gel, and intra-anal nitroglycerin ointment. Company press releases announced first-generic approvals for Clindagel (clindamycin phosphate 1% topical gel) and MetroGel-Vaginal (metronidazole vaginal gel 0.75%) in 2021, with U.S. manufacturing handled by partner Cosette Pharmaceuticals.
Patent-litigation posture. Solaris is an operating company, not a non-practicing entity. In the tracked data it appears once, as a defendant, with zero plaintiff-side cases — the standard profile of a drugmaker defending an ANDA/Hatch-Waxman suit rather than asserting patents. It holds no asserted portfolio in these records.
Notable case. Sun Pharmaceutical Industries Ltd. et al. v. Solaris Pharma Corporation (D.N.J., filed 2026-04-22) is the sole tracked matter. Sun alleges that Solaris's ANDA No. 220440 for generic bromfenac ophthalmic solution 0.075%, a proposed generic of Sun's BromSite, infringes U.S. RE50,218 under 35 U.S.C. §271(e)(2); docket listings also cite U.S. 8,778,999. The filing follows Solaris's March 2026 Paragraph IV notice. Venue is the District of New Jersey — the defendant's home district — not a plaintiff-friendly NPE forum.
Hatch-Waxman/DJ action filed by Sun against Solaris concerning Solaris's ANDA No. 220440 for bromfenac ophthalmic solution 0.075%, asserting U.S. Patent RE50,218, the reissue of the ’999 family, rather than the ’999 patent itself. The case was pending/just filed.